Navigation Links
Stereotaxis Showcases Interventional Value of Magnetic Navigation at TCT 2009

ST. LOUIS, Sept. 24 /PRNewswire-FirstCall/ -- Stereotaxis, Inc. (Nasdaq: STXS) is showcasing the value of its technologies for interventional procedures at the Transcatheter Cardiovascular Therapeutics (TCT) symposium in San Francisco this week. Stereotaxis pioneered remote magnetic navigation in electrophysiology and clinicians have repeatedly demonstrated the value of its technologies in the treatment of cardiac arrhythmias. More than 23,000 cases have been performed with the Magnetic Navigation System, and this clinical experience includes many compelling interventional procedures. In the cath lab as well as the EP lab, Stereotaxis' computer-controlled devices, integrated information systems and advanced networking tools deliver opportunities for hospitals and clinicians to simplify the treatment of complex cases and ultimately aim for enhanced patient care and improved outcomes.

On Monday, September 21, Dr. Gurpreet S. Sandhu of the Mayo Clinic presented data from his use of Stereotaxis' Magnetic Navigation System to treat chronic total occlusions. In his presentation "Beyond Guidewires: What Novel Technologies Help Today?" Dr. Sandhu highlighted the value of the Niobe system in the treatment of failed PCIs . Additionally, Dr. Jeffrey Moses of Columbia University Medical Center presented a live case in which he used the Stereotaxis three-dimensional vessel reconstruction to assist in the treatment of a chronic total occlusion in a patient who had previously undergone open heart surgery.

"Our Niobe System has been used to perform more procedures across the broadest range of cardiovascular applications than any other remote magnetic, robotic or mechanical navigation system presently available," said Michael P. Kaminski, Stereotaxis President and CEO. "In addition to its widespread adoption in EP labs, the Niobe System has been used in the treatment of patients with congenital heart defects and peripheral vascular occlusive disease, and we are very excited about the opportunities we see to extend the value of our magnetic navigation and information management technologies into these and other potential cardio-vascular applications."

At its TCT booth #600, Stereotaxis is showcasing its Pegasus(TM) Magnetic Guidewires and Odyssey(TM) System.

Pegasus Magnetic Guidewires

Stereotaxis recently introduced the Pegasus family of magnetically steerable guidewires. Pegasus is a blended stainless steel and Nitinol(TM) wire that provides exceptional and accurate omni-directional distal tip control. Its clinical advantages include excellent torque control and tip durability; optimal shaft support and device deliverability; and nearly effortless advancement through stenotic and tortuous vessel segments.

The Odyssey System

The Odyssey information backbone will be showcased by demonstrating the new Odyssey QuadHD ultra high resolution display and Odyssey Cinema, which synchronizes and archives lab data and can share a fully integrated view of a procedure with any laptop in the world on a high speed internet connection. This Odyssey portfolio is now designed to integrate standard labs, allowing all labs within a department to leverage the capabilities of remote lab viewing, recording and collaboration.

TCT is being held at the Moscone Center in San Francisco from September 21 to 25, 2009. For more information on Stereotaxis, please visit

About Stereotaxis

Stereotaxis designs, manufactures and markets an advanced cardiology instrument control system for use in a hospital's interventional surgical suite to enhance the treatment of coronary artery disease and arrhythmias. The Stereotaxis System is designed to enable physicians to complete more complex interventional procedures by providing image guided delivery of catheters and guidewires through the blood vessels and chambers of the heart to treatment sites. This is achieved using computer-controlled, externally applied magnetic fields that govern the motion of the working tip of the catheter or guidewire, resulting in improved navigation, shorter procedure time and reduced x-ray exposure. The core components of the Stereotaxis system have received regulatory clearance in the U.S., Europe, and Canada and elsewhere.

About Forward Looking Statements

This press release includes statements that may constitute "forward- looking" statements, usually containing the words "believe," "estimate," "project," "expect" or similar expressions. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, continued acceptance for the Company's products in the marketplace, competitive factors, changes in government reimbursement procedures, dependence upon third-party vendors, and other risks discussed in the Company's periodic and other filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release. There can be no assurance that we will recognize revenue related to our purchase orders and other commitments in any particular period or at all because some of these purchase orders and other commitments are subject to contingencies that are outside of our control. In addition, these orders and commitments may be revised, modified or canceled, either by their express terms, as a result of negotiations, or by project changes or delays.

SOURCE Stereotaxis, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Stereotaxis Awarded Exclusive Contract by Novation for Robotic Interventional Technology
2. Stereotaxis Names Daniel Johnston as Chief Financial Officer
3. Stereotaxis Reports 19% Second Quarter Revenue Growth
4. Stereotaxis Announces Second Quarter 2009 Earnings Release Date and Conference Call
5. Stereotaxis Market Leadership Highlighted at Heart Rhythm 2009
6. Stereotaxis Reports First Quarter 2009 Financial Results
7. Stereotaxis Announces First Quarter 2009 Earnings Release Date and Conference Call
8. Stereotaxis Extends Its Credit Facility With Silicon Valley Bank
9. Stereotaxis Signs Agreement With Leading Leasing Specialist to Offer Alternative Financing to Hospital Customers
10. Stereotaxis Announces First Uses of the NAVISTAR(R) RMT THERMOCOOL(R) Catheter
11. Stereotaxis Announces FDA Approval of the NAVISTAR(R) RMT THERMOCOOL(R) Catheter
Post Your Comments:
(Date:12/1/2015)... ... December 01, 2015 , ... Baptist Medical Center ... and is the only hospital in the region providing what is known as ... transcatheter pacing patients were revealed recently at a medical conference and published in ...
(Date:12/1/2015)... MD (PRWEB) , ... December 01, 2015 , ... ... salmon identification tests to continue the expansion of the company’s growing product line ... – for Chinook (Oncorhynchus tshawytscha) and Sockeye (Oncorhynchus nerka) – allow InstantLabs to ...
(Date:12/1/2015)... New York, NY (PRWEB) , ... December 01, ... ... cause of non-traumatic limb amputations in the United States. Podiatrists are well aware ... (failure to adopt therapeutic behaviors) are often catastrophic contributors to diseases of the ...
(Date:12/1/2015)... CA (PRWEB) , ... December 01, 2015 , ... ... Health Center of Excellence (BHCOE) today announced that the organization has awarded Education ... San Francisco, with a Distinguished Award. The award celebrates exceptional special needs providers ...
(Date:12/1/2015)... ... December 01, 2015 , ... ... for Effective Post-Affiliation Integration ,” addresses a main “pain point” for merging or ... anticipated results, once a deal is signed. This quick-read guidance suggests that ...
Breaking Medicine News(10 mins):
(Date:12/1/2015)... During the recent 2015 Transcatheter Cardiovascular ... CA , Medinol Ltd. continued to introduce ... a satellite symposium, "The BioNIR eDES: The Role ... a renowned physician panel discussed the key attributes ... Stent System and the Medinol eDES Coronary Stent ...
(Date:12/1/2015)... YORK , Dec. 1, 2015 Relmada Therapeutics, ... the treatment of chronic pain, announced today that the company ... will be held December 1-3 at the Luxe Sunset Boulevard ... Sergio Traversa , CEO of Relmada Therapeutics, will present on ... Eastern Time). . Please register at least ...
(Date:12/1/2015)... Dec. 1, 2015  InCarda Therapeutics, Inc. (InCarda), a ... of therapies for cardiovascular conditions via the inhalation route, ... in Australia . InCarda is planning ... Australia in the first half of ... medical centers in Adelaide and ...
Breaking Medicine Technology: